Not Signed In - Boehringer Ingelheim Provides Update On Study Arms Of Aptivus® (tipranavir) Clinical Trial In Treatment-naïve HIV-infected Patients
Sun, 26 Feb 2006 10:00 PM EST
... Boehringer Ingelheim is actively conducting a clinical trial program to further evaluate Aptivus® (tipranavir) capsules for the treatment of HIV-1 infection. The program is comprised of ongoing and planned studies in over 1,000 pediatric, antiretroviral-naïve, racially and gender diverse, or hepatitis co-infected patients... click link for more info. ...
Related Topics
- Clinical Trials
- HIV/AIDS & STDs
- HIV Testing
- Vaccinations For HIV/AIDs Patients
- Psychopharmacology
- HIV Antibody
- Pharmacology
- Pancreatic Cancer
- Trastuzumab
- Acquired Immune Deficiency Syndrome
- Crohn's Disease
- Tarceva
- What Your Female Patients Want to Know About Bladder Control
- Perinatal HIV
- Smoking Cessation and Continued Risk in Cancer Patients
- Depression
- Western/Clinical Treatment and Therapy
- Bevacizumab Injection
- Clinical Growth Charts
- Cardiovascular Health
email this page
print this page
bookmark this page
feedback on this page
